Pivotal New Data from Merck’s Broad Oncology Portfolio at ESMO 2019 Congress
Phase 3 Data for KEYTRUDA® (pembrolizumab) as Neoadjuvant Therapy in Combination with Chemotherapy in Patients with Triple-Negative Breast Cancer (KEYNOTE-522) to be Featured in ESMO Presidential Symposium and Official Press Program
Data for LYNPARZA Included in ESMO Presidential Symposium and Official Press Program: in Metastatic Castration-Resistant Prostate Cancer (PROfound) and in Advanced Ovarian Cancer (PAOLA-1)
KENILWORTH, N.J.–(BUSINESS WIRE)–Merck (NYSE: MRK), known as MSD outside the United States and Canada, today announced new data from its broad oncology portfolio and pipeline will be presented at the European Society for Medical Oncology (ESMO) 2019 Congress in Barcelona, Spain, from Sept. 27-Oct. 1, 2019. More than 80 abstracts involving Merck cancer medicines and investigational candidates will be featured at the congress, spanning over 18 tumor types.
Media Contacts:
Pamela Eisele
(267) 305-3558
Kristen Drake
(908) 740-167
Investor Contacts:
Peter Dannenbaum
(908) 740-1037
Courtney Ronaldo
(908) 740-613
